Literature DB >> 23271335

Tocilizumab treatment for recalcitrant uveitic macular edema.

Alfredo Adán1, Victor Llorenç, Marina Mesquida, Laura Pelegrín.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23271335     DOI： 10.1007/s00417-012-2243-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  5 in total

1.  Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?

Authors:  Christoph Tappeiner; Carsten Heinz; Gerd Ganser; Arnd Heiligenhaus
Journal:  J Rheumatol       Date:  2012-06       Impact factor: 4.666

2.  Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis.

Authors:  Aurore Muselier; Philip Bielefeld; Samuel Bidot; Julien Vinit; Jean-François Besancenot; Alain Bron
Journal:  Ocul Immunol Inflamm       Date:  2011-10       Impact factor: 3.070

3.  Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis.

Authors:  Takeru Yoshimura; Koh-Hei Sonoda; Nobuyuki Ohguro; Yoshiyuki Ohsugi; Tatsuro Ishibashi; Daniel J Cua; Takashi Kobayashi; Hiroki Yoshida; Akihiko Yoshimura
Journal:  Rheumatology (Oxford)       Date:  2009-01-22       Impact factor: 7.580

4.  Intraocular and serum cytokine profiles in patients with intermediate uveitis.

Authors:  Natasa Vidovic Valentincic; Jolanda D F de Groot-Mijnes; Aleksandra Kraut; Peter Korosec; Marko Hawlina; Aniki Rothova
Journal:  Mol Vis       Date:  2011-07-20       Impact factor: 2.367

5.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.

Authors:  P Emery; E Keystone; H P Tony; A Cantagrel; R van Vollenhoven; A Sanchez; E Alecock; J Lee; J Kremer
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103
  5 in total
  5 in total

Review 1.  IL-6 blockade in the management of non-infectious uveitis.

Authors:  Giuseppe Lopalco; Claudia Fabiani; Jurgen Sota; Orso Maria Lucherini; Gian Marco Tosi; Bruno Frediani; Florenzo Iannone; Mauro Galeazzi; Rossella Franceschini; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2017-05-20       Impact factor: 2.980

Review 2.  Interleukin-6 blockade in ocular inflammatory diseases.

Authors:  M Mesquida; A Leszczynska; V Llorenç; A Adán
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

3.  Tocilizumab treatment for refractory uveitis-related cystoid macular edema.

Authors:  Alfredo Adán; Marina Mesquida; Victor Llorenç; Gerard Espinosa; Blanca Molins; Maria V Hernández; Laura Pelegrín
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-07-27       Impact factor: 3.117

Review 4.  Pharmacotherapy for uveitis: current management and emerging therapy.

Authors:  Robert J Barry; Quan Dong Nguyen; Richard W Lee; Philip I Murray; Alastair K Denniston
Journal:  Clin Ophthalmol       Date:  2014-09-22

Review 5.  Drug discovery in ophthalmology: past success, present challenges, and future opportunities.

Authors:  Nicholas J D Gower; Robert J Barry; Matthew R Edmunds; Lucy C Titcomb; Alastair K Denniston
Journal:  BMC Ophthalmol       Date:  2016-01-16       Impact factor: 2.209
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.